Senju Pharma has launched a new drug for dry eye disease (DED) in Japan, Avarept, which is the first drug in the TRPV1 antagonist class to reach the market. Licensed from fellow Japanese drugmaker ...
Three years after buying Bellus Health and its chronic cough candidate camlipixant for around $2 billion, GSK is abandoning ...
In the biggest venture capital financing this week, clinical-stage radiopharmaceutical AdvanCell has closed a $315 million ...
All 15-year-old children in the UK should be offered the vaccine against meningitis B (MenB) in the wake of fatal outbreaks ...
MSD has won the race to bring an oral PCSK9 inhibitor through to regulatory approval in the US, after getting the go-ahead ...
Thousands of people in England and Wales with a type of chronic heart failure (CHF) could soon be eligible for treatment with ...
Just a few months after it was formed by a merger of two psychedelic drug developers, AtaiBeckley has been snapped up by Eli ...
For decades, pharmaceutical marketing has been built on a simple premise: if we present the right data, to the right audience ...
The European Commission has approved Novo Nordisk's pill formulation of weight-loss therapy Wegovy, making it the first oral ...
Amgen has reacted with consternation to the news that treatment with its KRAS inhibitor Lumykras will no longer be funded in ...
Hundreds of researchers at the Institute of Cancer Research (ICR) in London have held historic strikes across sites in Sutton ...
The steady stream of biotechs aiming to list on the Nasdaq has continued, with Attovia Therapeutics and Braveheart Bio the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results